HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.

doi:10.1016/j.ygyno.2023.03.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.

Gynecologic oncology - 1 May 2023

Bruce Shaina F, Wu Sharon, Ribeiro Jennifer R, Farrell Alex, Oberley Matthew J, Winer Ira, Erickson Britt K, Klc Tenley, Jones Nathaniel L, Thaker Premal H, Powell Matthew A

Abstract excerpt

OBJECTIVE: HER2 status is not routinely evaluated in endometrioid endometrial cancer (E-EMCA), though it is frequently overexpressed or amplified in high grade E-EMCA and uterine serous carcinoma. Defining characteristics and survival outcomes of HER2+ E-EMCA could reveal subsets of patients who may benefit from targeted therapies. METHODS: 2927 E-EMCA tumors from the Caris Life Sciences database were analyzed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Endometrioid
Share to Endometrial Neoplasms
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Tumor Microenvironment

Share to Uterine Neoplasms

Source

Open in PubMed

Identifiers

PMID: 37003074
DOI: 10.1016/j.ygyno.2023.03.008

Provenance

PubMed metadata and Literature Corpus relationships.